NZ Lymphoma / Leukaemia Research Review Issue 22

In this issue:

Stopping imatinib in CML with stable undetectable MRD
Arsenic trioxide then autologous SCT for relapsed APL
BR vs. R-CHOP as first-line treatment for indolent/MCL
R-BAC for MCL ineligible for intensive regimens or autologous SCT
R-CHOP in newly diagnosed DLBCL
Dose-adjusted EPOCH-R in primary mediastinal B-cell lymphoma
Intensifying frontline autologous SCT with BuCyE in PTCL
PCNSL prognosis after highdose chemotherapy and autologous SCT
Rituximab alone is enough in t(11;18)-negative GML

Please login below to download this issue (PDF)